The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells

Metastatic colorectal cancer (mCRC) remains a major public health problem, and diagnosis of metastatic disease is usually associated with poor prognosis. The multi-kinase inhibitor regorafenib was approved in 2013 in the U.S. for the treatment of mCRC patients who progressed after standard therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Ning, Chu, Edward, Wu, Shao-yu, Wipf, Peter, Schmitz, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467112/
https://www.ncbi.nlm.nih.gov/pubmed/25544765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467112/
https://www.ncbi.nlm.nih.gov/pubmed/25544765

Ejemplares similares